Literature DB >> 25899003

TFF2-CXCR4 Axis Is Associated with BRAF V600E Colon Cancer.

Manish K Gala1, Thomas Austin2, Shuji Ogino3, Andrew T Chan4.   

Abstract

Oncogene-induced senescence (OIS), a tumor-suppressive mechanism that is induced by the replicative and metabolic stress of oncogene activation, is a key barrier in the development of BRAF V600E colon cancer. Inhibition of this mechanism has been observed through epigenetic changes observed in sporadic serrated polyps, as well as through the germline mutations associated with those who develop serrated polyposis. We hypothesize that upregulated autocrine factors exist that are specific to the serrated pathway and also promote bypass of oncogene-induced senescence. To identify such autocrine factors, we integrate analyses of microarrays of sessile serrated polyps and two large colon cancer cohorts, the Cancer Genome Atlas (TCGA; n = 153), and French national Cartes d'Identité des Tumeurs (CIT) program (n = 462), with enhanced gene annotation through natural language processing techniques of the existing medical corpus. We reproducibly associate higher expression of the ligand-receptor axis of TFF2 and CXCR4 with BRAF V600E-mutant colon cancer (P = 3.0 × 10(-3) and 0.077, respectively for TCGA; P = 3.0 × 10(-8) and 5.1 × 10(-7) for CIT). Given well-described oncogenic roles of TFF2 and CXCR4 in colon cancer, and availability of CXCR4 inhibitors for other clinical indications, this ligand-receptor axis may represent an actionable target for prevention and treatment of this molecular subtype of colorectal cancer. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25899003      PMCID: PMC4490961          DOI: 10.1158/1940-6207.CAPR-14-0444

Source DB:  PubMed          Journal:  Cancer Prev Res (Phila)        ISSN: 1940-6215


  28 in total

1.  Correcting away the hidden heritability.

Authors:  Scott M Williams; Jonathan L Haines
Journal:  Ann Hum Genet       Date:  2011-02-24       Impact factor: 1.670

2.  EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.

Authors:  Ryan B Corcoran; Hiromichi Ebi; Alexa B Turke; Erin M Coffee; Michiya Nishino; Alexandria P Cogdill; Ronald D Brown; Patricia Della Pelle; Dora Dias-Santagata; Kenneth E Hung; Keith T Flaherty; Adriano Piris; Jennifer A Wargo; Jeffrey Settleman; Mari Mino-Kenudson; Jeffrey A Engelman
Journal:  Cancer Discov       Date:  2012-01-16       Impact factor: 39.397

3.  Regulation of CXCR4-mediated nuclear translocation of extracellular signal-related kinases 1 and 2.

Authors:  Ming Zhao; Richard G Discipio; Antonia G Wimmer; Ingrid U Schraufstatter
Journal:  Mol Pharmacol       Date:  2005-10-06       Impact factor: 4.436

4.  Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival.

Authors:  Joseph Kim; Hiroya Takeuchi; Stella T Lam; Roderick R Turner; He-Jing Wang; Christine Kuo; Leland Foshag; Anton J Bilchik; Dave S B Hoon
Journal:  J Clin Oncol       Date:  2005-04-20       Impact factor: 44.544

5.  CXCR4 Expression and Treatment with SDF-1α or Plerixafor Modulate Proliferation and Chemosensitivity of Colon Cancer Cells.

Authors:  Doreen Heckmann; Patrick Maier; Stephanie Laufs; Frederik Wenz; W Jens Zeller; Stefan Fruehauf; Heike Allgayer
Journal:  Transl Oncol       Date:  2013-04-01       Impact factor: 4.243

6.  Trefoil factor 1 acts to suppress senescence induced by oncogene activation during the cellular transformation process.

Authors:  Daniel R Radiloff; Timothy P Wakeman; Junjie Feng; Stephen Schilling; Edward Seto; Xiao-Fan Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2011-03-30       Impact factor: 11.205

7.  Trefoil factors: tumor progression markers and mitogens via EGFR/MAPK activation in cholangiocarcinoma.

Authors:  Kanuengnuch Kosriwong; Trevelyan R Menheniott; Andrew S Giraud; Patcharee Jearanaikoon; Banchob Sripa; Temduang Limpaiboon
Journal:  World J Gastroenterol       Date:  2011-03-28       Impact factor: 5.742

8.  Jetset: selecting the optimal microarray probe set to represent a gene.

Authors:  Qiyuan Li; Nicolai J Birkbak; Balazs Gyorffy; Zoltan Szallasi; Aron C Eklund
Journal:  BMC Bioinformatics       Date:  2011-12-15       Impact factor: 3.169

9.  Prevalence of different subtypes of serrated polyps and risk of synchronous advanced colorectal neoplasia in average-risk population undergoing first-time colonoscopy.

Authors:  Andrea Buda; Manuela De Bona; Isabella Dotti; Pierluca Piselli; Eva Zabeo; Renzo Barbazza; Angelo Bellumat; Flavio Valiante; Ermanno Nardon; Chris S Probert; Massimo Pignatelli; Giorgio Stanta; Giacomo Carlo Sturniolo; Michele De Boni
Journal:  Clin Transl Gastroenterol       Date:  2012-01-05       Impact factor: 4.488

10.  Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication.

Authors:  Paul Lochhead; Aya Kuchiba; Yu Imamura; Xiaoyun Liao; Mai Yamauchi; Reiko Nishihara; Zhi Rong Qian; Teppei Morikawa; Jeanne Shen; Jeffrey A Meyerhardt; Charles S Fuchs; Shuji Ogino
Journal:  J Natl Cancer Inst       Date:  2013-07-22       Impact factor: 13.506

View more
  4 in total

Review 1.  Structure, Function, and Therapeutic Potential of the Trefoil Factor Family in the Gastrointestinal Tract.

Authors:  Nayara Braga Emidio; Stuart M Brierley; Christina I Schroeder; Markus Muttenthaler
Journal:  ACS Pharmacol Transl Sci       Date:  2020-06-09

Review 2.  The IGF-II-Insulin Receptor Isoform-A Autocrine Signal in Cancer: Actionable Perspectives.

Authors:  Pierluigi Scalia; Antonio Giordano; Stephen J Williams
Journal:  Cancers (Basel)       Date:  2020-02-05       Impact factor: 6.639

3.  Heparanase modulates the prognosis and development of BRAF V600E-mutant colorectal cancer by regulating AKT/p27Kip1/Cyclin E2 pathway.

Authors:  Mengling Liu; Xiaojing Xu; Ke Peng; Pengcong Hou; Yitao Yuan; Suyao Li; Xun Sun; Zhongyi Shi; Jiayu Zhang; Yu Dong; Qing Liu; Luoyan Ai; Li Liang; Lu Gan; Qihong Huang; Yiyi Yu; Tianshu Liu
Journal:  Oncogenesis       Date:  2022-09-21       Impact factor: 6.524

Review 4.  BRAF Mutated Colorectal Cancer: New Treatment Approaches.

Authors:  Javier Molina-Cerrillo; María San Román; Javier Pozas; Teresa Alonso-Gordoa; Miguel Pozas; Elisa Conde; Marta Rosas; Enrique Grande; María Laura García-Bermejo; Alfredo Carrato
Journal:  Cancers (Basel)       Date:  2020-06-14       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.